favicon-300x300

ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology for a wide variety of applications.
 
Our founder, Dr. Emmanuelle Charpentier (the ‘E’in ERS) won the Nobel Prize the discovery of CRISPR/Cas9 in 2020. 

Without question, CRISPR/Cas9 has transformed the field of gene editing. At ERS Genomics, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.
 
 
 
 

 

BIO-Europe is the perfect time to start a conversation about your CRISPR license. We are excited to connect with companies who can benefit from this game-changing technology.
A meeting or a call with us is worthwhile for you if:

You are interested in possible use of CRISPR/Cas9 for internal research programs:
– Are you using modified cells or animals from an academic source?
– Are you generating in-house reagents?

 

You are interested in use of genetically modified cells in manufacturing. Including… 
– mAbs
– Gene or cell therapy
– Vectors
– Industrial enyzmes or intermediates

 

You provide any services which utilize CRISPR/Cas9 or cells or animals modified by the technology. Including…
– High-throughput screening 
– Target identification, Target validation
– Cell line development
– Disease specific cell models
– Animal models of disease

 

You have an interest in animal health applications. Including… 
– Disease resistance, Vaccines Trait improvements

 
 
Let’s schedule a meeting in Basel

Schedule time with Dr. Ralph Vogelsang, Senior Director, Business Development & Licensing, ERS Genomics

‘Your journey with CRISPR begins with a license from ERS Genomics. I am delighted to be back at BIO 2023. If you would like to learn more about CRISPR/Cas9 and licensing, connect with me and let’s talk.’

Schedule a Meeting
Bio Partnering

Licensing

Learn More

Intellectual Property

Learn More

Knowledge Centre

Learn More

Contact US

Learn More

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

CVC successfully appeals prior CRISPR U.S. patent decision

U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute with the Broad Institute.  Decision sent back to the PTAB for reconsideration under the correct legal standard for assessing the inventor of CRISPR-Cas9 gene editing in eukaryotic cells.    Dublin,.

Read Full Article

AI + CRISPR: Powering the 21st Century’s Biological Revolution 

We stand at the forefront of a pivotal moment in human innovation—where AI and CRISPR gene editing converge to power what can only be described as the 21st century’s biological revolution.  A New Industrial Epoch  Just as coal and steam powered the 19th-century Industrial Revolution and electricity and chemistry fuelled.

Read Full Article

Licensee Case Study: Bioneer

Making CRISPR more accessible for scientific innovation   At ERS Genomics, we make CRISPR/Cas9 accessible to innovators. By licensing the foundational IP co-owned by Professor Emmanuelle Charpentier, we enable a broad spectrum of applications outside of direct therapeutic use—from drug discovery to innovation in fields far beyond pharma. One of.

Read Full Article